Nothing Special   »   [go: up one dir, main page]

NO2010010I1 - Exendin-4 (Exenatid) - Google Patents

Exendin-4 (Exenatid)

Info

Publication number
NO2010010I1
NO2010010I1 NO2010010C NO2010010C NO2010010I1 NO 2010010 I1 NO2010010 I1 NO 2010010I1 NO 2010010 C NO2010010 C NO 2010010C NO 2010010 C NO2010010 C NO 2010010C NO 2010010 I1 NO2010010 I1 NO 2010010I1
Authority
NO
Norway
Prior art keywords
exendin
exenatide
modified
agonist
manufacture
Prior art date
Application number
NO2010010C
Other languages
English (en)
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27381821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2010010(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of NO2010010I1 publication Critical patent/NO2010010I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO2010010C 1999-01-14 2010-05-11 Exendin-4 (Exenatid) NO2010010I1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11638099P 1999-01-14 1999-01-14
US13201799P 1999-04-30 1999-04-30
US17536500P 2000-01-10 2000-01-10
PCT/US2000/000942 WO2000041548A2 (en) 1999-01-14 2000-01-14 Methods for glucagon suppression

Publications (1)

Publication Number Publication Date
NO2010010I1 true NO2010010I1 (no) 2010-06-07

Family

ID=27381821

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20013469A NO328077B1 (no) 1999-01-14 2001-07-12 Anvendelse av en eksendin eller eksendinagonist for fremstilling av en farmasoytisk formulering.
NO2010010C NO2010010I1 (no) 1999-01-14 2010-05-11 Exendin-4 (Exenatid)
NO2010012C NO2010012I1 (no) 1999-01-14 2010-05-20 Exennatid (Eksenatid)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20013469A NO328077B1 (no) 1999-01-14 2001-07-12 Anvendelse av en eksendin eller eksendinagonist for fremstilling av en farmasoytisk formulering.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2010012C NO2010012I1 (no) 1999-01-14 2010-05-20 Exennatid (Eksenatid)

Country Status (18)

Country Link
US (3) US6872700B1 (no)
EP (2) EP1658856B1 (no)
JP (1) JP2002538084A (no)
KR (2) KR20020001719A (no)
CN (1) CN100425284C (no)
AT (2) ATE460942T1 (no)
AU (2) AU770712B2 (no)
BR (1) BRPI0007823A8 (no)
CA (1) CA2356331C (no)
CY (1) CY1106347T1 (no)
DE (2) DE60044041D1 (no)
DK (1) DK1143989T3 (no)
ES (2) ES2278589T3 (no)
HK (1) HK1046105A1 (no)
NO (3) NO328077B1 (no)
NZ (1) NZ512657A (no)
PT (1) PT1143989E (no)
WO (1) WO2000041548A2 (no)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE493998T1 (de) * 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
KR100637433B1 (ko) * 2004-05-24 2006-10-20 삼성에스디아이 주식회사 발광 표시 장치
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
PT1143989E (pt) 1999-01-14 2007-03-30 Amylin Pharmaceuticals Inc Exendinas para supressão de glucagon
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
AU2014277804B2 (en) * 2001-07-31 2016-12-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1 exendin-4 peptide analogs and uses thereof
CA2463908A1 (en) * 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
DK1569680T3 (da) * 2002-10-22 2009-05-18 Waratah Pharmaceuticals Inc Behandling af diabetes
WO2004050115A2 (en) * 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2004093823A2 (en) * 2003-03-19 2004-11-04 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
BRPI0507189A (pt) * 2004-01-30 2007-06-26 Waratah Pharmaceuticals Inc uso combinado de um agonista de glp-1 e compostos de gastrina
DK1745078T3 (da) 2004-04-23 2009-10-26 Conjuchem Biotechnologies Inc Fremgangsmåde til oprensning af albuminkonjugater
EP1765408B1 (en) * 2004-07-08 2015-12-09 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
WO2006074051A2 (en) * 2004-12-30 2006-07-13 Diakine Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
US8716221B2 (en) * 2005-01-14 2014-05-06 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR101399911B1 (ko) * 2005-03-11 2014-06-19 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 옥트레오타이드의 방출 조절형 제형
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
CA2619426C (en) 2005-08-19 2016-06-21 Amylin Pharmaceuticals, Inc. Exendin for treating diabetes and reducing body weight
WO2007053946A1 (en) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
EP1968644B1 (en) 2005-12-16 2012-06-27 Nektar Therapeutics Polymer conjugates of glp-1
US20070269863A1 (en) * 2005-12-22 2007-11-22 Bridon Dominique P Process for the production of preformed conjugates of albumin and a therapeutic agent
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
MX2009001114A (es) 2006-08-09 2009-02-10 Intarcia Therapeutics Inc Sistemas de suministro osmotico y ensambles de piston.
CN102827284B (zh) * 2006-11-14 2015-07-29 上海仁会生物制药股份有限公司 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
KR100805208B1 (ko) * 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
CN105688191A (zh) * 2007-04-23 2016-06-22 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
JP2010539064A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療への適用のための甲状腺刺激ホルモン放出ホルモン
EP2231191A2 (en) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20110263496A1 (en) 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
AU2009262263B2 (en) 2008-06-25 2014-08-14 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
JP5744735B2 (ja) 2008-09-04 2015-07-08 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 非水性担体を用いた徐放性製剤
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
WO2010138671A1 (en) 2009-05-28 2010-12-02 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for sleep enhancement
KR101112578B1 (ko) * 2009-07-16 2012-02-16 성균관대학교산학협력단 엑센딘의 비강투여용 약제학적 조성물 및 이의 제조방법
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
DK2462246T3 (da) 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
AU2010321587A1 (en) 2009-11-23 2012-06-07 Amylin Pharmaceuticals, Inc. Polypeptide Conjugate
AU2010323117B2 (en) 2009-11-25 2015-09-03 Capsugel Belgium Nv Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion
KR20130098873A (ko) 2010-04-27 2013-09-05 질랜드 파마 에이/에스 Glp-1 수용체 작용제 및 가스트린의 펩타이드 접합체 및 그의 용도
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
CN103370083B (zh) 2010-09-28 2016-11-16 艾米琳制药有限责任公司 具有增强的作用持续时间的工程化多肽
EP2654767A4 (en) 2010-12-22 2014-05-21 Amylin Pharmaceuticals Inc GLP-1 RECEPTOR AGONISTS FOR ISLAND CELL TRANSPLANTATION
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012162547A2 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
KR101357117B1 (ko) * 2011-06-28 2014-02-06 비앤엘델리팜 주식회사 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
PT2729160T (pt) 2011-07-08 2019-07-08 Aegerion Pharmaceuticals Inc Polipéptidos modificados com uma maior duração da ação e uma imunogenicidade reduzida
US9382304B2 (en) 2011-07-08 2016-07-05 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action with reduced immunogenicity
CN104144704B (zh) 2011-11-03 2018-03-23 西兰制药公司 Glp‑1受体激动剂肽胃泌素缀合物
WO2013170636A1 (zh) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
EP2863954A1 (en) 2012-06-21 2015-04-29 Indiana University Research and Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
DK2875043T3 (en) 2012-07-23 2017-03-27 Zealand Pharma As glucagon
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CA2895156A1 (en) 2012-12-21 2014-06-26 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
HUE039616T2 (hu) 2013-10-17 2019-01-28 Zealand Pharma As Acilezett glükagon analógok
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
WO2015067716A1 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
CN105934257B (zh) 2013-12-06 2020-10-09 韩捷 用于含氮和羟基的药物的生物可逆引入基团
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
US10137170B2 (en) 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) * 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2716985C2 (ru) 2014-10-29 2020-03-17 Зилэнд Фарма А/С Соединения-агонисты gip и способы
AU2016247499B2 (en) 2015-04-16 2020-09-03 Zealand Pharma A/S Acylated glucagon analogue
PL3297654T3 (pl) 2015-05-22 2021-12-20 The Board Of Trustees Of The Leland Stanford Junior University Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
KR101661332B1 (ko) 2015-05-28 2016-09-29 (의료)길의료재단 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
CA2987766A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
WO2017112889A1 (en) 2015-12-23 2017-06-29 The Johns Hopkins University Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
BR112018012833A2 (pt) 2015-12-23 2018-12-04 Amgen Inc método de tratamento ou amenização de distúrbios metabólicos usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas do glp-1
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
EP3429608A4 (en) * 2016-03-16 2019-12-11 Prolynx LLC CONJUGATES WITH EXTENDED RELEASE OF EXENATIDE ANALOGS
SG10201913699QA (en) 2016-05-16 2020-03-30 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3515408A1 (en) 2016-09-23 2019-07-31 Delpor, Inc. Stable compositions for incretin mimetic compounds
US11020484B2 (en) 2016-11-21 2021-06-01 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
CN110088125B (zh) 2016-12-09 2023-10-03 西兰制药公司 酰化的glp-1/glp-2双重激动剂
WO2018115401A1 (en) * 2016-12-22 2018-06-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
BR112019024410A2 (pt) 2017-06-20 2020-07-14 Amgen Inc. método de tratamento ou melhoria de disfunções metabólicas usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas de glp 1
MX2021010737A (es) 2019-03-08 2021-09-28 Amgen Inc Terapia de combinacion por factor de diferenciacion del crecimiento 15.
CN110151980B (zh) * 2019-06-30 2022-12-09 中国药科大学 Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5452284A (en) * 1992-09-14 1995-09-19 Matsushita Electric Industrial Co., Ltd. Optical recording/reproducing medium and apparatus using land and groove encoded information signals and identification signals including position information
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
CZ69596A3 (en) 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
US5726969A (en) * 1994-12-28 1998-03-10 Matsushita Electric Industrial Co., Ltd. Optical recording medium having dual information surfaces
EP1005033B1 (en) * 1995-10-09 2001-09-19 Matsushita Electric Industrial Co., Ltd. An optical disk and an optical disk reproduction apparatus
EP1439534A3 (en) * 1995-10-09 2006-11-29 Matsushita Electric Industrial Co., Ltd. Optical disk, optical recorder, optical reproducer, cryptocommunication system and program license system
US5852599A (en) * 1996-01-26 1998-12-22 Sharp Kabushiki Kaisha Optical recording medium and optical recording/reproducing device, and manufacturing method of optical recording medium
US5883958A (en) * 1996-04-01 1999-03-16 Sony Corporation Method and device for data decryption, a method and device for device identification, a recording medium, a method of disk production, and a method and apparatus for disk recording
US5839443A (en) * 1996-05-16 1998-11-24 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
JP2856390B2 (ja) * 1996-07-26 1999-02-10 株式会社日立製作所 情報記録媒体及びそれを用いた記録再生方法
ATE316100T1 (de) * 1996-06-05 2006-02-15 Roche Diagnostics Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5686511A (en) 1996-06-28 1997-11-11 The Valspar Corporation Esterifying epoxy resin with carboxyl polymer and quenching
EP0818776B1 (en) * 1996-07-10 2008-02-13 Hitachi, Ltd. Optical disc apparatus accessing method and system therefor
ATE493998T1 (de) * 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6266299B1 (en) * 1996-12-19 2001-07-24 Matsushita Electric Industrial Co., Ltd. Magneto-optical disk having write-once identification marks and method for recording thereof
EP1629849B2 (en) 1997-01-07 2017-10-04 Amylin Pharmaceuticals, LLC Pharmaceutical compositions comprising exendins and agonists thereof
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
JPH1131357A (ja) * 1997-07-08 1999-02-02 Pioneer Electron Corp 情報データの記録方法
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2299425A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
JPH11196084A (ja) * 1997-10-31 1999-07-21 Matsushita Electric Ind Co Ltd 暗号化システム
ES2297902T5 (es) 1997-11-14 2013-07-09 Amylin Pharmaceuticals, Inc. Compuestos novedosos agonistas de exendina
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
ES2291017T3 (es) 1998-02-13 2008-02-16 Amylin Pharmaceuticals, Inc. Efectos inotropicos y diureticos de la exendina y glp-1.
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
PT1143989E (pt) 1999-01-14 2007-03-30 Amylin Pharmaceuticals Inc Exendinas para supressão de glucagon
AU777564B2 (en) 1999-01-14 2004-10-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof
US6451974B1 (en) * 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6519213B1 (en) * 1999-06-29 2003-02-11 Oak Technology, Inc. Method and apparatus for reading data from a disk

Also Published As

Publication number Publication date
WO2000041548A3 (en) 2001-11-29
DE60032331D1 (de) 2007-01-25
NO2010012I1 (no) 2010-06-07
US20050171019A1 (en) 2005-08-04
ES2343072T3 (es) 2010-07-22
AU770712B2 (en) 2004-02-26
ATE347901T1 (de) 2007-01-15
KR20070051948A (ko) 2007-05-18
JP2002538084A (ja) 2002-11-12
NZ512657A (en) 2004-01-30
DK1143989T3 (da) 2007-04-16
BR0007823A (pt) 2001-11-20
CA2356331C (en) 2009-10-13
US7407932B2 (en) 2008-08-05
AU2004202293B2 (en) 2007-09-20
EP1658856A1 (en) 2006-05-24
ES2278589T3 (es) 2007-08-16
NO20013469L (no) 2001-09-14
EP1143989A3 (en) 2002-09-11
AU2413600A (en) 2000-08-01
US6872700B1 (en) 2005-03-29
CY1106347T1 (el) 2011-10-12
CN100425284C (zh) 2008-10-15
DE60044041D1 (de) 2010-04-29
WO2000041548A2 (en) 2000-07-20
HK1046105A1 (zh) 2002-12-27
DE60032331T2 (de) 2007-06-21
EP1658856B1 (en) 2010-03-17
NO328077B1 (no) 2009-11-23
CN1347327A (zh) 2002-05-01
NO20013469D0 (no) 2001-07-12
BRPI0007823A8 (pt) 2017-03-21
AU2004202293A1 (en) 2004-06-17
CA2356331A1 (en) 2000-07-20
EP1143989B1 (en) 2006-12-13
ATE460942T1 (de) 2010-04-15
US7153825B2 (en) 2006-12-26
US20070037750A1 (en) 2007-02-15
PT1143989E (pt) 2007-03-30
KR20020001719A (ko) 2002-01-09
EP1143989A2 (en) 2001-10-17

Similar Documents

Publication Publication Date Title
NO2010010I1 (no) Exendin-4 (Exenatid)
DK1414486T3 (da) Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme
DE60124710D1 (de) Analoge des glucagon ähnlichen peptid-1
NO20022334D0 (no) Ny sammensetning og anvendelse
DE50015623D1 (de) Kovalent verbrückte insulindimere
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
ATE525083T1 (de) Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
DE60331458D1 (de) Kombinationschemotherapie mit chlorotoxin
AR033903A1 (es) Una composicion de insulina modificada quimicamente para la administracion pulmonar
DK1333887T3 (da) Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler
AU2002364035A1 (en) 4-sulfide / sulfoxide / sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
ITMI20011401A0 (it) Formulazioni farmaceutiche per ormoni tiroidei
NO20034097L (no) Hormonerstatningsterapi
DE602004005564D1 (de) Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten
NO20030759L (no) 10-aryl-11-HBENZO(b)fluorenderivater og analoger for medisinsk anvendelse
HUP0202592A2 (hu) Lazofoxifen transzdermális adagolása
ES2072442T3 (es) Composiciones farmaceuticas.
AR019724A2 (es) Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas
DK1372665T3 (da) Hormonerstatningsbehandling og administration
WO2003003971A3 (fr) Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
NO995940L (no) Anvendelse av leptin antagonister for behandling av diabetes
IT1312082B1 (it) Derivati morfinoidi, procedimento per la loro preparzione e loroimpiego terapeutico.
ES1053246Y (es) Dispositivo para recambiar botones utilizados en camisas.
ES1046918Y (es) Jeringuilla perfeccionada.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: AMYLIN PHARMACEUTICALS LLC, US

FC2A Withdrawal, rejection or dismissal of laid open patent application